Merck Taps Nuevolution to Help Identify Drug Targets | GenomeWeb
NEW YORK (GenomeWeb News) – Nuevolution said today that it will use its DNA labeling platform to identify small-molecule leads against drug targets in a collaboration with Merck.
 
Copenhagen-based Nuevolution said it will use its Chemetics platform to screen multi-million member libraries for hit identification, and to perform hit-to-lead optimization.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.